V2X, Inc. current report, 31 December 2020

Business Context and Reporting Period

This Form 8-K filing by Vectrus, Inc. (trading symbol: VEC) reports on events occurring on December 31, 2020. The registrant is incorporated in Indiana and operates primarily in Colorado Springs, CO. The filing details the completion of a strategic acquisition.

Key Financial Metrics and Transaction Details

  • Acquisition Consideration: Approximately $125 million in cash.
  • Target Company: Zenetex LLC.
  • Purchasing Entity: Vectrus Systems Corporation (VSC), a wholly owned subsidiary of Vectrus, Inc.
  • Funding Sources: Cash on hand and borrowings under the Company's existing credit facility.
  • Adjustments: The final consideration is subject to post-closing working capital and other adjustments as defined in the Share Purchase Agreement.

The filing text does not provide specific values for the Company's overall revenue, profit, cash flow, margins, total debt, or liquidity positions outside of the transaction funding details.

Material Changes

The primary material change reported is the successful closing of the acquisition of Zenetex LLC. This transaction expands the Company's asset base and operations, funded through a combination of internal liquidity and existing debt facilities.

Guidance, Outlook, and Risks

The filing does not contain updated financial guidance, forward-looking outlook statements, or specific risk factors related to the acquisition beyond the standard reference to the Share Purchase Agreement. The document notes that the summary of the agreement is qualified by the full text filed as Exhibit 2.1.

Investor Verification Checklist

  • Verify the final purchase price after post-closing working capital adjustments.
  • Review the impact of the acquisition on the Company's leverage ratios and remaining capacity under its existing credit facility.
  • Examine the full Share Purchase Agreement (Exhibit 2.1) for specific covenants, indemnities, and integration terms.
  • Confirm the strategic rationale and expected synergies of the Zenetex acquisition in subsequent earnings releases or 10-K filings.